Sugi Predict

Sugi Predict / Compounds / SCHEMBL10176854

SCHEMBL10176854

SCHEMBL10176854

CC(C)Cc1ccc2c(c1)N(C)CCO2

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 2/20 0.46
▸ PKM P14618 2/20 0.40
▸ TAAR1 Q96RJ0 2/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ PKLR P30613 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ CYP11B1 P15538 1/20 0.38
▸ CYP11B2 P19099 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10176850 0.89 PDE10A (0.47) RORCTAAR1SLC6A2SLC6A4SLC6A3
SCHEMBL10176852 0.84 RORC (0.51) RORCTAAR1SLC6A2SLC6A4SLC6A3
SCHEMBL2633104 0.82 PKM (0.42) PKMNPC1PKLRRAB9AALDH1A1
SCHEMBL20456067 0.81 NISCH (0.43) PKMNPC1PKLRRAB9ACYP11B1
SCHEMBL26504063 0.81 CD274 (0.41) PKMNPC1PKLRRAB9ACYP11B1
SCHEMBL19225665 0.78 PKM (0.41) PKMNPC1PKLRRAB9ACYP11B1
SCHEMBL22993498 0.78 PRMT5 (0.42) RORCTAAR1SLC6A2SLC6A4SLC6A3
SCHEMBL10159942 0.76 RORC (0.40) RORCTAAR1SLC6A2SLC6A4SLC6A3
SCHEMBL13160684 0.76 RORC (0.40) RORCTAAR1SLC6A2SLC6A4SLC6A3
SCHEMBL5018909 0.76 TAAR1 (0.59) TAAR1SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49080-E1 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2022-05-24 — — US disclosed
US-9895389-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2018-02-20 — — US disclosed
US-9895389-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2018-02-20 — — US disclosed
US-20170042925-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2017-02-16 — — US disclosed
US-20170042925-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2017-02-16 — — US disclosed
US-20150141354-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2015-05-21 — — US disclosed
US-20140274921-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2014-09-18 — — US disclosed
US-8828951-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2014-09-09 — — US disclosed
US-8466114-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2013-06-18 — — US disclosed
US-8394772-B2 Glycoside derivative and uses thereof NOVARTIS AG (CH) 2013-03-12 — — US disclosed
US-20130017993-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2013-01-17 — — US disclosed
US-20120196813-A1 GLYCOSIDE DERIVATIVE AND USES THEREOF NOVARTIS AG (CH) 2012-08-02 — — US disclosed
US-20120178680-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2012-07-12 — — US disclosed
US-8163704-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2012-04-24 — — US disclosed
US-20110171159-A1 Glycoside Derivatives and Uses Thereof NOVARTIS AG (CH) 2011-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170042925-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 RORC 1350/4885PKM 1453/4885TAAR1 4361/4885
US-20120178680-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 RORC 1350/4885PKM 1453/4885TAAR1 4361/4885
US-20150141354-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 RORC 1350/4885PKM 1453/4885TAAR1 4361/4885
US-20130017993-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 RORC 1350/4885PKM 1453/4885TAAR1 4361/4885
US-20110171159-A1 Glycoside Derivatives and Uses Thereof SLC5A1, SLC5A2, SLC2A1 RORC 1350/4885PKM 1453/4885TAAR1 4361/4885
US-20140274921-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 RORC 1350/4885PKM 1453/4885TAAR1 4361/4885
US-20120196813-A1 GLYCOSIDE DERIVATIVE AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 RORC 1554/4885PKM 1438/4885TAAR1 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.